Interestingly, also vaccines that stimulate endogenous TNF release are currently evaluated as a long-term modulating immuno-intervention in clinical trials in type 1 diabetes and have been investigated in MS (NCT02081326; NCT00607230; NCT00202410) [349,379]. The gene discussed is TNF; the disease is myeloid sarcoma.